Search

Displaying results 1911 - 1920 of 4207 in total
  1. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus erythematosus, but

  2. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...

  3. Drug

    Fucoxanthin

    go.drugbank.com/drugs/DB15462
    Investigational

    , but the exact mechanism of anti-cancer action of fucoxanthin is not fully elucidated. … Fucoxanthin causes antitumor and anticarcinogenic effects by inducing G1 cell-cycle arrest and apoptosis by modulating expression of various cellular molecules and cellular signal transduction pathways

  4. Drug

    Lemuteporfin

    go.drugbank.com/drugs/DB04980
    Investigational

    Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

  5. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. … It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.

  6. Drug

    Razuprotafib

    go.drugbank.com/drugs/DB16353
    Investigational

    Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. … [L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.

  7. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.

  8. Drug

    Mitomycin

    go.drugbank.com/drugs/DB00305
    ApprovedInvestigational

    Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_. … [L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix.

  9. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    [A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and [tamoxifen] have been developed to reduce adverse events through selective pharmacological actions on tissue-specific

  10. Drug

    Stiripentol

    go.drugbank.com/drugs/DB09118
    ApprovedInvestigational

    Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs. The clinical development and marketing of stiripentol were first delayed due to the drug's...